Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML

Affiliations

• ¹ Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany.
• ² Data Integration for Future Medicine (DIFUTURE), LMU Munich, Munich, Germany.
• ³ Department of Medicine III, Laboratory for Leukemia Diagnostics, University Hospital, LMU Munich, Munich, Germany.
• ⁴ Department of Hematology, Oncology and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine Berlin, Berlin, Germany.
• ⁵ Institute of Human Genetics, University Hospital, LMU Munich, Munich, Germany.
• ⁶ Department of Haematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
• ⁷ Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
• ⁸ Foundation for the Finnish Cancer Institute, Helsinki, Finland.
• ⁹ Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
• ¹⁰ Department of Medicine A, Hematology and Oncology, University of Münster, Münster, Germany.
• ¹¹ German Society of Hematology and Oncology, Berlin, Germany.
• ¹² Department of Medicine III, Hospital Leverkusen, Leverkusen, Germany.
• ¹³ Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany.
• ¹⁴ German Cancer Consortium, Heidelberg, Germany.
• ¹⁵ German Cancer Research Center, Heidelberg, Germany.
• ¹⁶ Department of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.